Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The rationale of the study is to explore the safety and efficacy of ofatumumab in combination
with dexamethasone (O-dex regimen) in patients with refractory/relapsed CLL. Moreover, the
hypothesis is that this approach will be able to achieve at least the same response rates
compared with R-dex regimens (historical controls; manuscript submitted to Leukemia), while
maintaining lower toxicity profile.
Phase:
Phase 2
Details
Lead Sponsor:
Brno University Hospital
Collaborators:
Faculty Hospital Kralovske Vinohrady General Teaching Hospital, Prague University Hospital Hradec Kralove